Autolus Therapeutics (AUTL) Prepaid Assets (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly Prepaid Assets came in at $76.5 million in Q4 2025, up 13.58% YoY from $67.3 million in Q4 2024, and down 10.39% on a QoQ basis from $85.3 million in Q3 2025.
Analysis
Autolus Therapeutics (AUTL) Prepaid Assets (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Prepaid Assets data on file, last reported at $76.5 million in Q4 2025.
- Quarterly Prepaid Assets rose 13.58% year-over-year to $76.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $76.5 million (up 13.58% YoY) and the FY2025 annual result came in at $76.5 million, up 13.58% from the prior year.
- Prepaid Assets slipped to $76.5 million in Q4 2025, from $85.3 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $85.3 million in Q3 2025 to a low of $35.0 million in Q4 2023.
- A 5-year average of $54.1 million and a median of $51.0 million in 2023 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets decreased 24.01% — and 2024, when it surged 92.55%.
- Tracing AUTL's Prepaid Assets over 5 years: stood at $36.3 million in 2021, then grew by 18.56% to $43.0 million in 2022, then slipped by 18.7% to $35.0 million in 2023, then soared by 92.55% to $67.3 million in 2024, then grew by 13.58% to $76.5 million in 2025.
- The last three Prepaid Assets figures came in at $76.5 million (Q4 2025), $85.3 million (Q3 2025), and $67.9 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Autolus Therapeutics | 594.86 Mn | 393.23 Mn | 25.22 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 55.14 Mn |
| Dec 31, 2025 | 76.47 Mn |
| Sep 30, 2025 | 85.34 Mn |
| Jun 30, 2025 | 67.88 Mn |
| Mar 31, 2025 | 68.78 Mn |
| Dec 31, 2024 | 67.33 Mn |
| Sep 30, 2024 | 59.58 Mn |
| Jun 30, 2024 | 51.64 Mn |
| Mar 31, 2024 | 44.75 Mn |
| Dec 31, 2023 | 34.97 Mn |
| Sep 30, 2023 | 51.53 Mn |
| Jun 30, 2023 | 47.53 Mn |
| Mar 31, 2023 | 50.53 Mn |
| Dec 31, 2022 | 43.01 Mn |
| Sep 30, 2022 | 48.94 Mn |
| Jun 30, 2022 | 42.20 Mn |
| Mar 31, 2022 | 40.57 Mn |
| Dec 31, 2021 | 36.28 Mn |
| Sep 30, 2021 | 64.41 Mn |
| Jun 30, 2021 | 52.94 Mn |